# Noninvasive Peripheral Nerve Stimulation for Medication-Refractory Primary RLS (The RESTFUL Study)

> **NCT04874155** · NA · COMPLETED · sponsor: **Noctrix Health, Inc.** · enrollment: 133 (actual)

## Conditions studied

- Restless Legs Syndrome

## Interventions

- **DEVICE:** NTX100 Neuromodulation System - Active
- **DEVICE:** NTX100 Neuromodulation System - Sham
- **DEVICE:** NTX100 Neuromodulation System - Open-Label

## Key facts

- **NCT ID:** NCT04874155
- **Lead sponsor:** Noctrix Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-06
- **Primary completion:** 2022-03-18
- **Final completion:** 2022-04-08
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2024-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04874155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04874155, "Noninvasive Peripheral Nerve Stimulation for Medication-Refractory Primary RLS (The RESTFUL Study)". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04874155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*